Free Trial
NASDAQ:ENLV

Enlivex Therapeutics (ENLV) Stock Price, News & Analysis

Enlivex Therapeutics logo
$1.45 -0.04 (-2.68%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.45 0.00 (0.00%)
As of 08/1/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Enlivex Therapeutics Stock (NASDAQ:ENLV)

Key Stats

Today's Range
$1.41
$1.52
50-Day Range
$0.91
$1.54
52-Week Range
$0.81
$1.76
Volume
250,283 shs
Average Volume
231,549 shs
Market Capitalization
$34.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Enlivex Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

ENLV MarketRank™: 

Enlivex Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 524th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enlivex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Enlivex Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Enlivex Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Enlivex Therapeutics are expected to grow in the coming year, from ($0.70) to ($0.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enlivex Therapeutics is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enlivex Therapeutics is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enlivex Therapeutics has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Enlivex Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.24% of the outstanding shares of Enlivex Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Enlivex Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enlivex Therapeutics has recently increased by 51.67%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Enlivex Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Enlivex Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.24% of the outstanding shares of Enlivex Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Enlivex Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enlivex Therapeutics has recently increased by 51.67%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Enlivex Therapeutics has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Enlivex Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    3 people have searched for ENLV on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Enlivex Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.02% of the stock of Enlivex Therapeutics is held by institutions.

  • Read more about Enlivex Therapeutics' insider trading history.
Receive ENLV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENLV Stock News Headlines

Market Crash Warning: How to Protect Your Wealth Before August 12th
New China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shifting out of stocks, while everyday investors remain exposed. A free guide reveals where the smart money is going—and how to protect your wealth before the next sell-off.
See More Headlines

ENLV Stock Analysis - Frequently Asked Questions

Enlivex Therapeutics' stock was trading at $1.17 at the beginning of the year. Since then, ENLV shares have increased by 23.9% and is now trading at $1.45.

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) announced its earnings results on Friday, May, 30th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01.

Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enlivex Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), CrowdStrike (CRWD), Adobe (ADBE) and Meta Platforms (META).

Company Calendar

Last Earnings
5/30/2025
Today
8/03/2025
Next Earnings (Estimated)
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENLV
CIK
1596812
Employees
70
Year Founded
N/A

Price Target and Rating

High Price Target
$13.00
Low Price Target
$7.00
Potential Upside/Downside
+589.7%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.66)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.01 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-57.67%
Return on Assets
-50.52%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.20
Quick Ratio
7.20

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.00 per share
Price / Book
1.45

Miscellaneous

Outstanding Shares
23,650,000
Free Float
20,747,000
Market Cap
$34.29 million
Optionable
Optionable
Beta
0.80

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:ENLV) was last updated on 8/3/2025 by MarketBeat.com Staff
From Our Partners